Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3194414 | 0.86 | L3MBTL1 (0.56) | KDM4EALDH1A1L3MBTL1LMNAPPARA | |
| SCHEMBL1240716 | 0.86 | L3MBTL1 (0.56) | KDM4EALDH1A1L3MBTL1LMNAPPARA | |
| SCHEMBL12204139 | 0.83 | LTA4H (0.42) | KDM4EALDH1A1HRH3LMNALTA4H | |
| SCHEMBL1241562 | 0.81 | L3MBTL1 (0.55) | KDM4EALDH1A1L3MBTL1LMNAPPARA | |
| SCHEMBL25031568 | 0.80 | L3MBTL1 (0.33) | L3MBTL1 | |
| SCHEMBL22447961 | 0.79 | KMT2A (0.45) | KDM4EALDH1A1HRH3LMNAMEN1 | |
| SCHEMBL2660428 | 0.79 | CA14 (0.34) | — | |
| SCHEMBL1240735 | 0.79 | CA14 (0.34) | — | |
| SCHEMBL12750822 | 0.78 | HSD11B1 (0.40) | ALDH1A1L3MBTL1LMNAKMT2APPARA | |
| SCHEMBL16491284 | 0.77 | LSS (0.50) | KDM4EALDH1A1L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362049-B2 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2013-01-29 | — | — | US | disclosed |
| US-8318778-B2 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2012-11-27 | — | — | US | disclosed |
| US-20120165375-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2012-06-28 | — | — | US | disclosed |
| US-20100041711-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2010-02-18 | — | — | US | disclosed |
| EP-2099777-A1 | UREA GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008084044-A1 | UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041711-A1 | Urea Glucokinase Activators | GCK, GCKR, HK2 | KDM4E 2001/4885ALDH1A1 2703/4885L3MBTL1 4720/4885 |
| US-20120165375-A1 | Urea Glucokinase Activators | GCK, GCKR, HK2 | KDM4E 2001/4885ALDH1A1 2703/4885L3MBTL1 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.